C. David Sjöström

24.8k total citations · 5 hit papers
116 papers, 12.1k citations indexed

About

C. David Sjöström is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Nephrology. According to data from OpenAlex, C. David Sjöström has authored 116 papers receiving a total of 12.1k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Endocrinology, Diabetes and Metabolism, 48 papers in Surgery and 26 papers in Nephrology. Recurrent topics in C. David Sjöström's work include Diabetes Treatment and Management (68 papers), Pancreatic function and diabetes (30 papers) and Diabetes Management and Research (24 papers). C. David Sjöström is often cited by papers focused on Diabetes Treatment and Management (68 papers), Pancreatic function and diabetes (30 papers) and Diabetes Management and Research (24 papers). C. David Sjöström collaborates with scholars based in Sweden, United States and Denmark. C. David Sjöström's co-authors include Lars Sjöström, Hans Wedel, Hiddo J.L. Heerspink, Markku Peltonen, Bergur V. Stefánsson, David C. Wheeler, Peter Rossing, Glenn M. Chertow, Ricardo Correa‐Rotter and John J.V. McMurray and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

C. David Sjöström

115 papers receiving 11.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery

2004 3.2k citations Lars Sjöström, Markku Peltonen et al. profile →
Dapagliflozin in Patients with Chronic Kidney Disease

2020 3.0k citations Hiddo J.L. Heerspink, Bergur V. Stefánsson et al. profile →
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

2013 389 citations C. David Sjöström et al. Diabetes Obesity and Metabolism profile →
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

2020 355 citations David C. Wheeler, Bergur V. Stefánsson et al. The Lancet Diabetes & Endocrinology profile →
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

2021 237 citations David C. Wheeler, Robert D. Toto et al. profile →

Peers

C. David Sjöström

EDM

SURGE

PHYSI

NEPHR

Sangeeta R. Kashyap United States

Guntram Schernthaner Austria

Ofri Mosenzon Israel

David R. Hadden United Kingdom

Steven P. Marso United States

Giancarlo Viberti United Kingdom

David Z.I. Cherney Canada

Peter Gæde Denmark

Greg Fulcher Australia

Avivit Cahn Israel

Sangeeta R. Kashyap United States

C. David Sjöström

3.4k ×0.6

EDM

7.7k ×1.4

SURGE

5.1k ×1.7

PHYSI

1.6k ×0.7

430 ×0.2

NEPHR

Citations per year, relative to C. David Sjöström C. David Sjöström (= 1×) peers Sangeeta R. Kashyap

Countries citing papers authored by C. David Sjöström

Since Specialization

Citations

This map shows the geographic impact of C. David Sjöström's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. David Sjöström with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. David Sjöström more than expected).

Fields of papers citing papers by C. David Sjöström

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. David Sjöström. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. David Sjöström. The network helps show where C. David Sjöström may publish in the future.

Co-authorship network of co-authors of C. David Sjöström

This figure shows the co-authorship network connecting the top 25 collaborators of C. David Sjöström. A scholar is included among the top collaborators of C. David Sjöström based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. David Sjöström. C. David Sjöström is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heerspink, Hiddo J.L., Austin G. Stack, Robert Terkeltaub, et al.. (2024). Combination Treatment with Verinurad and Allopurinol in CKD. Journal of the American Society of Nephrology. 35(5). 594–606. 15 indexed citations

McEwan, Phil, Jason A. Davis, Juan José García Sánchez, et al.. (2024). The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis. Nephrology Dialysis Transplantation. 39(12). 2040–2047. 8 indexed citations

Persson, Frederik, Niels Jongs, Gozewijn D. Laverman, et al.. (2023). Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study. Diabetes Care. 46(3). 602–607. 9 indexed citations

Regan, Jessica A., Robert J. Mentz, Jennifer B. Green, et al.. (2023). Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes. JCI Insight. 8(17). 9 indexed citations

Chertow, Glenn M., Ricardo Correa‐Rotter, Priya Vart, et al.. (2023). Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial. Journal of the American Heart Association. 12(9). e028739–e028739. 18 indexed citations

Tamborlane, William V., Raafat Bishai, David H. Geller, et al.. (2022). Once-Weekly Exenatide in Youth With Type 2 Diabetes. Diabetes Care. 45(8). 1833–1840. 60 indexed citations

Behrens, C.F., L. Calmels, C. David Sjöström, et al.. (2022). Online adaptive radiotherapy of urinary bladder cancer with full re-optimization to the anatomy of the day: Initial experience and dosimetric benefits. Radiotherapy and Oncology. 171. 37–42. 55 indexed citations

Chertow, Glenn M., Priya Vart, Niels Jongs, et al.. (2021). Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. UCL Discovery (University College London). 80 indexed citations

McMurray, John J.V., David C. Wheeler, Bergur V. Stefánsson, et al.. (2021). Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. JACC Heart Failure. 9(11). 807–820. 62 indexed citations

10.

Jongs, Niels, Tom Greene, Glenn M. Chertow, et al.. (2021). Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. The Lancet Diabetes & Endocrinology. 9(11). 755–766. 126 indexed citations

11.

Sibolt, Patrik, Lina Andersson, L. Calmels, et al.. (2020). Results of a Pilot Study on Online Adaptive Radiotherapy of Bladder Cancer with Artificial Intelligence-driven Full Re-optimization on the Anatomy of the Day. International Journal of Radiation Oncology*Biology*Physics. 108(3). S79–S80. 5 indexed citations

12.

Clegg, Lindsay E., Robert C. Penland, David W. Boulton, et al.. (2020). Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial. Diabetes Obesity and Metabolism. 22(12). 2493–2498. 25 indexed citations

13.

Shulman, Alexander, Johanna C. Andersson‐Assarsson, C. David Sjöström, et al.. (2020). Remission and progression of pre-existing micro- and macroalbuminuria over 15 years after bariatric surgery in Swedish Obese Subjects study. International Journal of Obesity. 45(3). 535–546. 16 indexed citations

14.

Raalte, Daniël H. van, Cristian Guja, Klaas Hoogenberg, et al.. (2020). Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials. Diabetes Obesity and Metabolism. 22(9). 1556–1566. 23 indexed citations

15.

Stefánsson, Bergur V., Hiddo J.L. Heerspink, David C. Wheeler, et al.. (2020). Correction of anemia by dapagliflozin in patients with type 2 diabetes. Journal of Diabetes and its Complications. 34(12). 107729–107729. 32 indexed citations

16.

Shulman, Alexander, Markku Peltonen, C. David Sjöström, et al.. (2018). Incidence of end-stage renal disease following bariatric surgery in the Swedish Obese Subjects Study. International Journal of Obesity. 42(5). 964–973. 56 indexed citations

17.

Marshall, Nathaniel S., Ronald R. Grunstein, Markku Peltonen, et al.. (2011). Self-reported sleep apnoea and mortality in patients from the Swedish Obese Subjects study. European Respiratory Journal. 38(6). 1349–1354. 12 indexed citations

18.

Jernås, Margareta, Bob Olsson, Kajsa Sjöholm, et al.. (2008). Changes in adipose tissue gene expression and plasma levels of adipokines and acute-phase proteins in patients with critical illness. Metabolism. 58(1). 102–108. 40 indexed citations

19.

Sjöström, C. David. (2002). Prevalence of sleep apnoea and snoring in hypertensive men: a population based study. Thorax. 57(7). 602–607. 97 indexed citations

20.

Lindberg, Eva, C. David Sjöström, Ahmed Elmasry, & Christer Janson. (2000). Sleep apnea and snoring men with hypertension. American Journal of Respiratory and Critical Care Medicine. 161. 681. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact